DDInter699 DDInter1763
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Etodolac {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Etodolac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Etodolac {u} (Compound) downregulates {v} (Gene) RAI14
RAI14 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Etodolac {u} (Compound) upregulates {v} (Gene) MAL
MAL {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Etodolac {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Etodolac {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Etodolac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is associated with {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Temsirolimus
Etodolac {u} (Compound) downregulates {v} (Gene) RAI14
RAI14 {u} (Gene) is regulated by {v} (Gene) CREBL2
CREBL2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Etodolac {u} (Compound) upregulates {v} (Gene) MAL
MAL {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Etodolac {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Etodolac may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Etodolac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Temsirolimus (Compound)
Etodolac (Compound) downregulates RAI14 (Gene) and RAI14 (Gene) is upregulated by Temsirolimus (Compound)
Etodolac (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Temsirolimus (Compound)
Etodolac (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Temsirolimus (Compound)
Etodolac may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Etodolac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is associated with kidney cancer (Disease) and kidney cancer (Disease) is treated by Temsirolimus (Compound)
Etodolac (Compound) downregulates RAI14 (Gene) and RAI14 (Gene) is regulated by CREBL2 (Gene) and CREBL2 (Gene) is upregulated by Temsirolimus (Compound)
Etodolac (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)
Etodolac (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Temsirolimus (Compound)